Treatment of metastatic renal cell carcinoma with constant-rate floxuridine infusion pins recombinant α2b-interferon

Annals of Oncology

Volumn 7, Issue 6, 1996, Pages 601-605

  Falcone, A ^a   Cianci, C ^a   Pfanner, E ^a   Ricci, S ^a   Lencioni, M ^a   Brunetti, I ^a   Giulianotti, P C ^b   Vannucci, L ^b   Mosca, F ^b   Conte, P F ^a  

^a SANTA CHIARA HOSPITAL   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Floxuridine; Interferon; Metastatic; Phase II; Renal carcinoma

Indexed keywords

ALPHA2B INTERFERON; FLOXURIDINE;

ADULT; AGED; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; FATIGUE; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; MALE; METASTASIS; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; VOMITING;

EID: 9444283118     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010677     Document Type: Article

References (41)

1. De Forges A, Rey A, Klink M et al. Prognostic factors of adult renal carcinoma: Multivariate analyses. Semin Surg Oncol 1988; 4: 149-54.
2. Giuliani L. Giberti C, Martorana G et al. Radical extensive surgery for renal cell carcinoma: Long term results and prognostic factors. J Urol 1990; 143: 468-74.
3. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 1995; 22: 42-60.
4. WM Linehan WM, Shipley WV, Parkinson DR. Cancer of the kidney and ureter. In De Vita VT Jr, Hellmann S, Rosenberg SA (eds): Cancer: Principle and Practice of Oncology (ed 4). Philadelphia, PA: Lippincott 1993; 1023-51.
5. Boccardo F. Therapeutic challenges in the medical management of renal cancer. Forum 1991; 2: 143-62.
6. Fossa SD, Kramar A, Droz JP. Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-a. Eur J Cancer 1994; 30A: 1310-4.
7. Jones M, Philip T, Palmer P et al. The impact of interleukin-2 on survival in renal cancer: A multivariate analysis. Cancer Biother 1993; 8: 275-88.
8. Neidhart JA, Anderson SA, Harris JE et al. Vinblasine fails to improve response of renal cancer to interferon alfa-n1: High response rate in patients with pulmonary metastases. J Clin Oncol 1991; 9: 832-7.
9. Sertoli MR, Brunetti I, Ardizzoni A et al. Recombinant alpha- 2a interferon plus vinblastine in the treatment of metastatic renal cell carcinoma. Am J Clin Oncol 1989; 12: 43-5.
10. Hrushesky WJM, von Roemeling R, Lanning RM et al. Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma. J Clin Oncol 1990; 8: 1504-13.
11. Huben RP. Advances in chemotherapy for renal cell carcinoma. Semin Urol 1992; 10: 16-22.
12. Wilkinson M, Stagg R, Grobman B et al. A phase II study of constant rate FUDR infusion in patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 1990; 9: 139.
13. Damascelli B, Marchianò A, Spreafico C et al. Circadian continous chemotherapy of renal cell carcinoma with an implantable programmable infusion pump. Cancer 1990; 66: 237-41.
14. Bjarnason JA, Hrushesky WJM, Diasio R et al. Flat versus circadian modified 14 day infusion of FUDR for advanced renal cell cancer: A phase III study. Proc Am Soc Clin Oncol 1994; 13: 233.
15. Elias L, Crissman HA. Interferon effect upon the adenocarcinoma 38 and HL-60 cell lines: Antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites. Cancer Res 1988; 48: 4868-73.
16. Chu E, Zinn S, Allegra C. Translational regulation of thymidylate synthase in response to 5-fluorouracil and gamma- interferon in a human colon cancer cell line. Cancer Res 1990; 50: 5834-9.
17. Houghton JA, Morton CL, Adkins DA et al. Locus of the interaction among 5-fluorouracil, leucovorin, and interferon a-2a in colon carcinoma cells. Cancer Res 1993; 53: 4243-50.
18. Wadler S, Lemberesky B, Atkins M et al. Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma. J Clin Oncol 1991; 9: 1806-10.
19. Grem JL, McAtee N, Murphy RF et al. A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma. J Clin Oncol 1991; 9: 1811-20.
20. Falcone A, Cianci C, Ricci S et al. Alpha-2B interferon plus floxuridine in metastatic renal cell carcinoma. A phase I-II study. Cancer 1993; 72: 564-8.
21. Fossa SD, Gunderson R, Moe B. Recombinant interferon- alpha combined with prednisone in metastatic renal cell carcinoma. Cancer 1990; 65: 2541-4.
22. Fossa SD. Improved subjective tolerability of interferon by combination with prednisolone. Eur J Clin Oncol 1987; 23: 875-6.
23. Miller AB, Hoogstraten B, Staquet M. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
24. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials 1989; 10: 1-10.
25. Palmer PA, Vinke J, Philip T et al. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol 1992; 3: 475-80.
26. Brouty-Boye D, Tovey MG. Inhibition by interferon of thymidine uptake in chemostat cultures of L1210 cells. Intervirology 1978; 9: 243-52.
27. Gewert DR, Shah S, Clemens MJ. Inhibition of cell division by interferons: Changes in the transport and intracellular metabolism of thymidine in human lymphoblastoid (Daudi) cells. Eur J Biochem 1981; 116: 487-92.
28. Gewert DR, Moore G, Clemens MJ. Inhibition of cell division by interferons: The relationship between changes in utilization of thymidine for DNA synthesis and control of proliferation in Daudi cells. Biochem J 1983; 214: 983-90.
29. Danhauser LL, Freiman JH, Gilchrist TL et al. Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer. J Clin Oncol 1993; 11: 751-61.
30. Yee LK, Allegra CJ, Steinberg SM et al. Decreased catabolism of fluorouracil in peripheral blood mononuclear cells during combination therapy with fluorouracil, leucovorin, and interferon α-2a. J Natl Cancer Inst 1992; 84: 1820-5.
31. Hill M, Norman A, Cunningham D et al. Royal Marsden phase III trial of fluorouracil with or without interferon alfa 2b in advanced colorectal cancer. J Clin Oncol 1995; 13: 1297-302.
32. Kohne CH, Schmoll HJ, Wilke H et al. Weekly high dose infusional 5-fluorouracil (FU) plus leucovorin (LV) vs. FU plus α- interferon (IFN) vs. FU plus LV plus IFN in advanced colorectal cancer. Results of a multicenter randomized trial. Proc Am Soc Clin Oncol 1994; 14: 194.
33. Seymour MT, Slevin M, Cunningham D et al. A randomized assessment of interferon-α2a as a modulator of 5-fluorouracil and leucovorin in advanced colorectal cancer. Proc Am Ass Clin Oncol 1994; 13: 209.
34. Dimopulos MA, Dexeus FH, Jones E et al. Evidence of additive anti-tumor activity and toxicity for the combination of FUDR and interferon alpha2B in patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 1991; 32: 186.
35. Soori G, Schuloff R, Stark J et al. Phase II trial of continuous infusion floxuridine and interferon-alpha-2b in advanced renal cancer - an NBSG study. Proc Am Soc Clin Oncol 1991; 12: 236.
36. Stadler VM, Vogelzang NJ, Voke EE et al. Continous infusion fluorodeoxyuridine with leucovorin and high-dose interferon: A phase II study in metastatic renal-cell cancer. Cancer Chemother Pharmacol 1992; 31: 213-6.
37. Sella A, Logothetis CJ, Fitz K et al. Recombinant interferon-α combined with 5-fluorouracil based chemotherapy in metastatic renal cell cancer. J Urol 1991; 145(2): 273A.
38. Murphy BR, Rynard SM, Einhorn LH et al. A Hoosier Oncology group study: A phase II trial of interferon alpha-2A plus fluorouracil in advanced renal cell carcinoma. Invest New Drugs 1992; 10: 225-30.
39. Schuth J, Goldschmidt, JW, Tunn UW. Response in patients with metastatic renal cell carcinoma during the treatment with alpha interferon in combination with 5-fluorouracil. Eur J Cancer 1993; 29 (Suppl 6): 234.
40. Sella A, Zukiwski A, Robinson E et al. Interleukin-2 with interferon-a and 5-fluorouracil in patients with metastatic renal cell cancer. Proc Am Soc Clin Oncol 1994; 13: 237.
41. Atzpodien J, Kirchner H, Hanninen EL et al. Interleukin-2 in combination with interferon-a and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer 1993; 29A (Suppl 5): S6-S8.